Antibodies against extractable nuclear antigen in non-Hodgkin lymphoma patients

Scandinavian Journal of Immunology

Volumn 61, Issue 4, 2005, Pages 343-346

  Gergely, L ^a   Danko A ^a   Csipo I ^a   Varoczy L ^a   Sipka, S ^a   Zeher, M ^a   Illes A ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BLEOMYCIN; CELL NUCLEUS ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 18344389905     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01567.x     Document Type: Article

References (12)

1. Guyomard S, Salles G, Coudurier M et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol 2003;123:90-9.
2. Solans-Laque R, Perez-Bocanegra C, Salud-Salvia A et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 2004;13:159-64.
3. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leuk Lymphoma 1992;7:117-22.
4. Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases - a descriptive epidemiological study. Rheumatol Int 2002;22:233-7.
5. Pusterla S, Previtali S, Marziali S et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5:341-6.
6. Bar-Dayan Y, Barshack I, Blank M et al. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int J Oncol 1999;15:1091-6.
7. Hamburger M, Hodes S, Barland P. The incidence and clinical significance of antibodies to extractable nuclear antigens. Am J Med Sci 1977;273:21-8.
8. Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand J Immunol 2002;56:456-69.
9. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
10. Segundo C, Medina F, Rodriguez C, Martinez-Palencia R, Leyva-Cobian F, Brieva JA. Surface molecule loss and bleb formation by human germinal center B cells undergoing apoptosis: role of apoptotic blebs in monocyte chemotaxis. Blood 1999;94:1012-20.
11. Frankfurt OS, Krishan A. Apoptosis-based drug screening and detection of selective toxicity to cancer cells. Anticancer Drugs 2003;14:555-61.
12. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I. The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma 2000;40:119-22.